glucocorticoid-induced osteoporosis
Endocrinology · 2008–2010
2decisions
2medicines
0carried consumer input
0individual submissions
Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alendronic acid treatment or prevention of glucocorticoid-induced osteoporosis in patients currently on long-term (at least 3 months), high-dose (at least 7.5 mg per day… | Jul 2010 | Recommended with restriction | no section in document |
| teriparatide Treatment of glucocorticoid-induced osteoporosis (GIOP) and severe established osteoporosis in patients at high risk of fracture. | Nov 2008 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.